Effect of m-Health-Based Interventions on Blood Pressure: An Updated Systematic Review with Meta-Analysis.

Background: In recent years, the integration of mobile health (m-Health) interventions has garnered increasing attention as a potential means to improve blood pressure (BP) management in adults. This updated systematic review with meta-analysis aimed to identify the effect of m-Health-based interventions on BP in adults and to evaluate the effect of m-Health on BP according to the characteristics of subjects, interventions, and countries. Methods: The search was carried out in PubMed, Embase, ResearchGate, and Cochrane databases in January 2022. Study selection and data extraction were performed by two independent reviewers. For analysis, random effects models were used with a confidence interval (CI) of 95% and p < 0.05. Results: Fifty studies were included in this review and in the meta-analysis. Interventions with m-Health reduced systolic BP in 3.5 mmHg (95% CI -4.3; -2.7; p < 0.001; I2 = 85.8%) and diastolic BP in 1.8 mmHg (95% CI -2.3; -1.4; p < 0.001; I2 = 78.9%) compared to usual care. The effects of m-Health interventions on BP were more evident in men and in older adults, in interventions lasting 6-8 weeks, with medication reminders, with the possibility of insertion of BP values (p < 0.05). Conclusion: The results of this study support the effectiveness of m-Health in reducing BP when compared to standard care. However, these effects are dependent on the characteristics of the subjects and interventions. Given the substantial heterogeneity among the results of this systematic review with meta-analysis, its interpretation should be cautious. Future research on this topic is warranted.

Acute Blood Pressure Response to Different Types of Isometric Exercise: A Systematic Review with Meta-Analysis.

Background: This study aimed to identify the blood pressure (BP) responses during different types of isometric exercises (IE) in adults and to evaluate whether BP responses according to IE is influenced by the characteristics of participants and exercise protocols. Methods: The search was conducted in PubMed, Cochrane Central, SPORTDiscus, and LILACS databases in June 2020. Random effects models with a 95% confidence interval and p < 0.05 were used in the analyses. Results: Initially, 3201 articles were found and, finally, 102 studies were included in this systematic review, seven of which were included in the meta-analysis comparing handgrip to other IE. Two-knee extension and deadlift promoted greater increases in systolic (+9.8 mmHg; p = 0.017; I 2 = 74.5% and +26.8 mmHg; p ≤ 0.001; I 2 = 0%, respectively) and diastolic (+7.9 mmHg; p = 0.022; I 2 = 68.6% and +12.4 mmHg; p ≤ 0.001; I 2 = 36.3%, respectively) BP compared to handgrip. Men, middle-aged/elderly adults, hypertensive individuals, and protocols with higher intensities potentiate the BP responses to handgrip exercise (p ≤ 0.001). Conclusions: IE involving larger muscle groups elicit greater BP responses than those involving smaller muscle masses, especially in men, middle-aged/elderly adults and hypertensive individuals. Future studies should directly compare BP responses during various types of IE in different populations.

Assessing the performance of commercial serological tests for SARS-CoV-2 diagnosis.

Objectives: The emergence of SARS-CoV-2 has triggered a global pandemic with profound implications for public health. Rapid changes in the pandemic landscape and limitations in in vitro diagnostics led to the introduction of numerous diagnostic devices with variable performance. In this study, we evaluated three commercial serological assays in Brazil for detecting anti-SARS-CoV-2 antibodies. Methods: We collected 90 serum samples from SARS-CoV-2-negative blood donors and 352 from SARS-CoV-2-positive, unvaccinated patients, categorized by symptom onset. Subsequently, we assessed the diagnostic performance of three commercial enzyme immunoassays: GOLD ELISA (enzyme-linked immunosorbent assay) COVID-19 Ig (immunoglobulin) G + IgM, Anti-SARS-CoV-2 NCP IgM ELISA, and Anti-SARS-CoV-2 NCP IgG ELISA. Results: Our findings revealed that the GOLD ELISA COVID-19 IgG + IgM exhibited the highest sensitivity (57.7%) and diagnostic odds ratio, surpassing the manufacturer's reported sensitivity in most analyzed time frames while maintaining exceptional specificity (98.9%). Conversely, the Anti-SARS-CoV-2 NCP IgG ELISA demonstrated lower sensitivity but aligned with independent evaluations, boasting a specificity of 100%. However, the Anti-SARS-CoV-2 NCP IgM ELISA exhibited lower sensitivity than claimed, particularly in samples collected shortly after positive reverse transcription polymerase chain reaction results. Performance improved 15-21 days after symptom onset and beyond 22 days, but in the first week, both Anti-SARS-CoV-2 NCP IgM ELISA and Anti-SARS-CoV-2 NCP IgG ELISA struggled to differentiate positive and negative samples. Conclusions: Our study emphasizes the need for standardized validation protocols to address discrepancies between manufacturer-claimed and actual performance. These insights provide essential information for health care practitioners and policymakers regarding the diagnostic capabilities of these assays in various clinical scenarios.

Comprehensive analysis of early T cell responses to acute Zika Virus infection during the first epidemic in Bahia, Brazil.

BACKGROUND: In most cases, Zika virus (ZIKV) causes a self-limited acute illness in adults, characterized by mild clinical symptoms that resolve within a few days. Immune responses, both innate and adaptive, play a central role in controlling and eliminating virus-infected cells during the early stages of infection. AIM: To test the hypothesis that circulating T cells exhibit phenotypic and functional activation characteristics during the viremic phase of ZIKV infection. METHODS: A comprehensive analysis using mass cytometry was performed on peripheral blood mononuclear cells obtained from patients with acute ZIKV infection (as confirmed by RT-PCR) and compared with that from healthy donors (HD). The frequency of IFN-γ-producing T cells in response to peptide pools covering immunogenic regions of structural and nonstructural ZIKV proteins was quantified using an ELISpot assay. RESULTS: Circulating CD4+ and CD8+ T lymphocytes from ZIKV-infected patients expressed higher levels of IFN-γ and pSTAT-5, as well as cell surface markers associated with proliferation (Ki-67), activation ((HLA-DR, CD38) or exhaustion (PD1 and CTLA-4), compared to those from HD. Activation of CD4+ and CD8+ memory T cell subsets, including Transitional Memory T Cells (TTM), Effector Memory T cells (TEM), and Effector Memory T cells Re-expressing CD45RA (TEMRA), was prominent among CD4+ T cell subset of ZIKV-infected patients and was associated with increased levels of IFN-γ, pSTAT-5, Ki-67, CTLA-4, and PD1, as compared to HD. Additionally, approximately 30% of ZIKV-infected patients exhibited a T cell response primarily directed against the ZIKV NS5 protein. CONCLUSION: Circulating T lymphocytes spontaneously produce IFN-γ and express elevated levels of pSTAT-5 during the early phase of ZIKV infection whereas recognition of ZIKV antigen results in the generation of virus-specific IFN-γ-producing T cells.

Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19.

Objectives: This study evaluated the performance of recombinant receptor binding domain (RBD) protein-based enzyme-linked immunosorbent assays (RBD-ELISAs) for detecting anti-SARS-CoV-2 immunoglobulin (Ig) G and IgM antibodies. Methods: In this study, 705 sera from SARS-CoV-2-infected individuals and 315 sera from healthy individuals were analyzed. Results: The RBD-ELISA IgG exhibited high specificity (99.1%) and moderate sensitivity (48.0%), with an overall diagnostic accuracy of 73.5%. RBD-ELISA IgM demonstrated specificity at 94.6% and sensitivity at 51.1%, with an accuracy of 72.8%. Both assays displayed improved performance when analyzing samples collected 15-21 days post-symptom onset, achieving sensitivity and accuracy exceeding 88% and 90%, respectively. Combining RBD-ELISA IgG and IgM in parallel analysis enhanced sensitivity to 98.6% and accuracy to 96.2%. Comparing these RBD-ELISAs with commercially available tests, the study found overlapping sensitivity and similar specificity values. Notably, the combined RBD-ELISA IgG and IgM showed superior performance. Cross-reactivity analysis revealed low false-positive rates (4.4% for IgG, 3.7% for IgM), primarily with viral infections. Conclusion: This research underscores the potential of RBD-based ELISAs for COVID-19 diagnosis, especially when assessing samples collected 15-21 days post-symptom onset and utilizing a parallel testing approach. The RBD protein's immunogenicity and specificity make it a valuable tool for serodiagnosis, offering an alternative to polymerase chain reaction-based methods, particularly in resource-limited settings.

Comprehensive Study of the IBMP ELISA IgA/IgM/IgG COVID-19 Kit for SARS-CoV-2 Antibody Detection.

COVID-19 laboratory diagnosis primarily relies on molecular tests, highly sensitive during early infection stages with high viral loads. As the disease progresses, sensitivity decreases, requiring antibody detection. Since the beginning of the pandemic, serological tests have been developed and made available in Brazil, but their diagnostic performance varies. This study evaluated the IBMP ELISA IgA/IgM/IgG COVID-19 kit performance in detecting SARS-CoV-2 antibodies. A total of 90 samples, including 64 from COVID-19 patients and 26 pre-pandemic donors, were assessed based on time post symptom onset (0-7, 8-14, and 15-21 days). The kit showed 61% sensitivity, 100% specificity, and 72% accuracy overall. Sensitivity varied with time, being 25%, 57%, and 96% for 0-7, 8-14, and 15-21 days, respectively. Similar variations were noted in other commercial tests. The Gold ELISA COVID-19 (IgG/IgM) had sensitivities of 31%, 71%, and 100%, while the Anti-SARS-CoV-2 NCP ELISA (IgG) and Anti-SARS-CoV-2 NCP ELISA (IgM) showed varying sensitivities. The IBMP ELISA kit displayed high diagnostic capability, especially as the disease progressed, complementing COVID-19 diagnosis. Reproducibility assessment revealed minimal systematic and analytical errors. In conclusion, the IBMP ELISA IgA/IgM/IgG COVID-19 kit is a robust tool for detecting anti-SARS-CoV-2 antibodies, increasing in efficacy over the disease course, and minimizing false negatives in RT-PCR COVID-19 diagnosis.

Genomic monitoring unveils a high prevalence of severe acute respiratory syndrome coronavirus 2 Omicron variant in vaccine breakthrough cases in Bahia, Brazil

SUMMARY OBJECTIVE: Genome sequencing has been proved to be an excellent tool to monitor the molecular epidemiology of the disease caused by severe acute respiratory syndrome coronavirus 2, i.e., coronavirus disease 2019. Some reports of infected, vaccinated individuals have aroused great interest because they are primarily being infected with circulating variants of concern. To investigate the cases of infected, vaccinated individuals in Salvador, Bahia, Brazil, we performed genomic monitoring to estimate the magnitude of the different variants of concern in these cases. METHODS: Nasopharyngeal swabs from infected (symptomatic and asymptomatic), vaccinated or unvaccinated individuals (n=29), and quantitative reverse transcription polymerase chain reaction cycle threshold value (Ct values) of ≤30 were subjected to viral sequencing using nanopore technology. RESULTS: Our analysis revealed that the Omicron variant was found in 99% of cases and the Delta variant was found in only one case. Infected, fully vaccinated patients have a favorable clinical prognosis; however, within the community, they become viral carriers with the aggravating factor of viral dissemination of variants of concern not neutralized by the currently available vaccines. CONCLUSION: It is important to acknowledge the limitations of these vaccines and to develop new vaccines to emergent variants of concern, as is the case of influenza vaccine; going through new doses of the same coronavirus vaccines is "more of the same."

Reabilitação funcional e barreiras para atividade física na COVID-longa: um ensaio clínico randomizado / Functional rehabilitation and barriers to physical activity after COVID-19: a randomized clinical trial

O estudo teve como objetivo analisar as barreiras percebidas à prática de atividade física durante um programa de treinamento multicomponente em adultos e idosos pós infecção por COVID-19. Realizou-se um ensaio clínico randomizado com 40 participantes (19 grupo controle e 21 grupo intervenção). Foram coletadas informações sociodemográficas, de saúde e de barreiras para a prática de atividade física, antes, 12 e 24 semanas após o início da intervenção. A medida das barreiras para a prática de atividade física foi obtida por meio de uma escala válida composta por 16 itens. As diferen-ças de barreiras entre os grupos e ao longo de tempo foi analisada a partir das Equações de Estimativa Generalizada, α = 0,05. As barreiras mais citadas pelos dois grupos na linha de base foram "Preguiça, cansaço ou desânimo" (71%), "Dores, lesões ou incapacidade" (38%) e "Falta de motivação" (48%). As análises principais indicaram que ambos os grupos tiveram redução na frequência da barreira "Pre-guiça, cansaço ou desânimo" na 12ª semana (p = 0,003), porém voltando aos valores iniciais na 24ª semana (p = 0,441). Já a barreira "Por causa da epidemia de coronavírus" foi reduzida na 12ª semana (p = 0,704) e ainda mais reduzida na 24ª semana (p = 0,158), comportamento também similar entre os grupos. Como principal conclusão, barreiras para atividade física podem ser reduzidas pela parti-cipação em programas de exercício supervisionado e recomendação para a prática de atividade física

The study aimed to analyze perceived barriers to physical activity during a multicomponent training pro-gram in adults and seniors post-COVID-19 infection. A randomized clinical trial was conducted with 40 participants (19 control group and 21 intervention group). Sociodemographic, health, and barriers to physical activity information were collected before, 12 and 24 weeks after the start of the intervention. The measure of barriers to physical activity was obtained through a valid scale composed of 16 items. Differences in barriers between groups and over time were analyzed using Generalized Estimating Equations, α = 0.05. The most frequently mentioned barriers at baseline by both groups were "Laziness, fatigue, or lack of enthusiasm" (71%), "Pain, injuries, or disability" (38%), and "Lack of motivation" (48%). The main analyses indicated that both groups had a reduction in the frequency of the barrier "Laziness, fatigue, or lack of enthusiasm" at week 12 (p = 0.003), but returned to initial values at week 24 (p = 0.441). The barrier "Because of the coronavirus epidemic" was reduced in week 12 (p = 0.704) and further reduced in week 24 (p = 0.158), with a similar pattern between groups. The key conclusion is that barriers to physical activity can be reduced through participation in supervised exercise programs and recommendations for physical activity

Óbitos por Covid -19 no estado da Bahia: da captação à publicação / Deaths by Covid -19 in the state of Bahia: from capture to publication / Muertes por Covid -19 en el estado de Bahía: desde la captura hasta la publicación

Identificada inicialmente em Wuhan, na China, a Covid-19 causada pelo novo coronavírus da síndrome respiratória (SARS-CoV-2) provocou um alerta global. Diante desse cenário emergencial, o Brasil, assim como outros países, tem vivenciando grandes mudanças nas ações e serviços em saúde. Na Bahia, a velocidade de disseminação da doença ocasionou um aumento significativo na notificação de casos e óbitos, promovendo uma restruturação no processo de trabalho da vigilância epidemiológica estadual para atuar de forma oportuna na captação, investigação e classificação de casos, e publicação e recomendações de medidas sanitárias. Este trabalho objetiva descrever o processo de trabalho na vigilância epidemiológica de óbitos por Covid-19 no estado da Bahia. Trata-se de um relato de experiência do processo de trabalho de análise dos óbitos por Covid-19 no período de março a dezembro de 2020. A trajetória metodológica foi estruturada em análise documental, relatórios de investigação, ferramentas de notificação do Ministério da Saúde e outros sistemas oficiais, como o Formulário Eletrônico do SUS ­ FormSUS, produzido pela Diretoria de Vigilância Epidemiológica para identificar os óbitos por Covid-19 nos hospitais da Bahia em tempo hábil, facilitando o processo de captação, investigação, análise e publicação de informação de mortalidade. Observou-se que a estruturação de um processo organizado e aplicado ao fluxo de trabalho possibilitou a qualificação e a fidedignidade das informações dos óbitos por Covid-19, garantindo mudanças incrementais no âmbito da vigilância e segurança das informações publicadas, essenciais para o planejamento das ações de prevenção e controle.

Initially identified in Wuhan, China, Covid-19 caused by the respiratory syndrome coronavirus (SARS-CoV-2) has triggered a global alert. Faced with this emergency scenario, Brazil, like other countries, has been experiencing major changes in health actions and services. In the state of Bahia, the rapid spread of the disease increased significantly the notification of cases and deaths, promoting a restructuring in the work process of state epidemiological surveillance to act in a timely manner in capturing, investigating and classifying cases, publishing and recommending sanitary measures. This paper aims at describing the work process in the epidemiological surveillance of deaths by Covid-19 in the state of Bahia. This is an experience report of Covid-19 death analysis work process, from March to December 2020. The methodological trajectory was structured in document analysis, investigation reports, notification tools from the Ministry of Health and others official systems, and the SUS FormSUS Electronic Form, produced by the Epidemiological Surveillance Directorate (Divep) to identify deaths by Covid-19 by hospitals in Bahia in a timely manner, facilitating the process of capturing, investigating, analyzing and publishing information of mortality. It was observed that the structuring of an organized process and application to the workflow enabled the qualification and reliability of death information by Covid-19, ensuring incremental changes in the scope of surveillance and security in the published information, essential for planning prevention and control actions.

Inicialmente identificado en Wuhan, China, el covid-19 causante del síndrome respiratorio agudo grave (SARS-CoV-2) ha desencadenado una alerta global. Ante este escenario de emergencia, Brasil, al igual que otros países, ha venido experimentando importantes cambios en las acciones y servicios de salud. En Bahía, la velocidad de propagación de la enfermedad provocó un aumento significativo en la notificación de casos y defunciones, promoviendo una reestructuración en el proceso de trabajo de la vigilancia epidemiológica estadual para actuar de manera oportuna en la recopilación, investigación, clasificación de casos, publicación y recomendación de medidas preventivas. Este artículo tiene como objetivo describir el proceso de trabajo en la vigilancia epidemiológica de las muertes por covid-19 en el estado de Bahía. Es un informe de experiencia del proceso de trabajo de análisis de muertes por covid-19, de marzo a diciembre de 2020. La trayectoria metodológica se estructuró en análisis de documentos, informes de investigación, herramientas de notificación del Ministerio de Salud y otros sistemas oficiales, así como el Formulario Electrónico SUS FormSUS, elaborado por la Dirección de Vigilancia Epidemiológica (Divep) para identificar las muertes por covid-19 en los hospitales de Bahía de manera oportuna, lo que facilita el proceso de recopilación, investigación, análisis y publicación de información sobre mortalidad. Se observó que la estructuración de un proceso organizado y aplicado al flujo de trabajo permitió la calificación y confiabilidad de la información de muertes por covid-19, asegurando cambios incrementales en el alcance de la vigilancia y seguridad de la información publicada, fundamental para planificar la prevención y el control.

Clinical and laboratory findings of acute Zika virus infection in patients from Salvador during the first Brazilian epidemic

Abstract Several major epidemics of Zika fever, caused by the ZIKA virus (ZIKV), have emerged in Brazil since early 2015, eventually spreading to other countries on the South American continent. The present study describes the clinical manifestations and laboratory findings of patients with confirmed acute ZIKV infection during the first epidemic that occurred in Salvador, Brazil. All included patients were seen at the emergency room of a private tertiary hospital located in Salvador, Brazil from 2015 through 2017. Patients were considered eligible if signs of systemic viral febrile disease were present. All individuals were tested for ZIKV and Chikungunya infection using PCR, while rapid test was used to detect Dengue virus antibodies or, alternatively, the NS1 antigen. A diagnosis of acute ZIKV infection was confirmed in 78/434 (18%) individuals with systemic viral febrile illness. Positivity was mainly observed in blood, followed by saliva and urine. Coinfection with Chikungunya and/or Dengue virus was detected in 5% of the ZIKV-infected patients. The most frequent clinical findings were myalgia, arthralgia and low-grade fever. Laboratory analysis demonstrated normal levels of hematocrit, platelets and liver enzymes. In summary, in acute settings where molecular testing remains unavailable, clinicians face difficulties to confirm the diagnosis of ZIKV infection, as they rely only on clinical examinations and conventional laboratory tests.

Síndrome de leigh: a propósito de um caso clínico com mutação no dna mitocondrial / Leigh syndrome: a case report with a mitochondrial dna mutation

RESUMO Objetivo: A síndrome de Leigh é uma doença neurodegenerativa com incidência de 1:40.000 nados-vivos. Apresenta ampla heterogeneidade clínica, bioquímica e genética, mas com alterações neuropatorradiológicas homogêneas. Não existe tratamento específico, e o prognóstico é reservado. O objetivo deste estudo foi familiarizar os profissionais de saúde com a doença. Descrição do caso: Menina de 16 meses, com hipotonia axial e atraso do desenvolvimento psicomotor. Dos exames realizados: cariótipo, potenciais auditivos evocados e avaliação oftalmológica normais; presença de hiperlactacidemia e hipocitrulinemia. Após a realização de ressonância magnética cerebral sob anestesia, observou-se agravamento da hipotonia com necessidade de internação por episódios de cianose/apneia. O eletroencefalograma não mostrou atividade epileptiforme. A neuroimagem revelou hipersinal lenticular bilateral com lesão do putâmen e do globo pálido esquerdo. Encontrou-se a mutação 8993T>G (MT-ATP6) no DNA mitocondrial. Comentários: De 10 a 30% dos doentes com síndrome de Leigh apresentam mutações do DNA mitocondrial. A descompensação com agravamento neurológico após intervenção anestésica está descrita e, nesse caso, apoiou o diagnóstico. Importante alertar para casos semelhantes, com diminuição de exames invasivos para diagnóstico.

ABSTRACT Objective: Leigh syndrome is a neurodegenerative disorder with an incidence of 1:40,000 live births. It presents wide clinical, biochemical, and genetic heterogeneity, but with homogenous neuropatoradiological alterations. There is no specific treatment, and the prognosis is reserved. This case report aimed familiarize health professionals with the disease. Case Description: A 16-month-hold girl who was followed in outpatient clinic due to axial hypotonia and delayed psychomotor development. Karyotype, auditory evoked potentials and ophthalmologic evaluation were normal. Evidence of hyperlactacidemia and hypocitrullinemia was detected in the patient. After performing brain magnetic resonance under anesthesia, hypotonia got worse, and the patient was hospitalized after an episode of cyanosis and apnea. The electroencephalogram showed no epileptiform activity. Neuroimaging revealed bilateral lenticular hyperintensity, especially in the putamen and in the left globus pallidus regions. Molecular analysis revealed an 8993T>G (MT-ATP6) mutation in the mitochondrial DNA. Comments: Between 10 and 30% of individuals with Leigh syndrome have mitochondrial DNA mutations. The decompensation after anesthetic intercurrences is typically associated with neurological deterioration and, in this case, increased the diagnosis suspicion. It is important to alert for similar cases and to reduce invasive diagnostic tests if the diagnosis is suspected.

Perfil clínico-laboratorial e da imunidade celular de pacientes com infecção aguda pelo vírus zika (zikv)

Introdução: As manifestações clínicas e laboratoriais da infecção pelo vírus da Zika (ZIKV) eram desconhecidas quando a doença passou a ser identificada no Brasil em 2015. Os relatos clínicos eram baseados em pequenas séries de casos e o diagnóstico de ZIKV era baseado em técnicas sorológicas que apresentavam reação cruzada com anticorpos anti-vírus da Dengue (DENV). Além disso era necessário caracterizar a resposta imune celular em pacientes com quadros agudos de ZIKV, muito pouco estudada até o início do presente estudo. Objetivo: Descrever as manifestações clínicas, os achados laboratoriais, e a resposta imune celular de pacientes com infecção aguda pelo ZIKV. Metodologia: Foi realizado um estudo descritivo clínico de corte transversal com pacientes selecionados em um pronto- atendimento na cidade de Salvador. Foram avaliados sequencialmente os pacientes com quadro sugestivo de infecção viral aguda entre 27 de maio de 2015 e 31 de agosto de 2017. O diagnóstico de ZIKV foi baseado na positividade ao rt-PCR no sangue ou urina ou saliva. Os pacientes também foram avaliados para infecção por Dengue ou Chikungunya (CHIKV) através do rt-PCR. Foi aplicado questionário para coleta de informações clínicas e laboratoriais. A fim de avaliar a resposta imune celular específica ao ZIKV, células mononucleares do sangue periférico (PBMC) foram obtidas de alguns pacientes no momento da inclusão no estudo (fase 1, P1) e após 15 dias (fase 2, P2). A partir do PBMC, foi avaliada a produção de interferon- gama em resposta a peptídeos recobrindo as proteínas do ZIKV, DENV e CHIKV por ELISPOT. A avaliação da assinatura imunológica dos linfócitos T foi realizada por citometria de massa (Cytof), utilizando um painel de 40 anticorpos. Resultados: Foram incluídos 78 pacientes no estudo clínico, sendo 66,7% do sexo feminino e média de idade de 38 anos. Os achados clínicos mais frequentes foram mialgia, artralgia e febre baixa. A análise laboratorial demonstrou níveis normais de hematócrito, plaquetas e enzimas hepáticas. Foi proposto um algoritmo para diagnóstico clínico de infecção pelo ZIKV. No estudo da resposta imune celular foram incluídos 29 indivíduos: 11 infectados por ZIKV, 11 por CHIKV, e 7 doadores de sangue como controles. Três dos 11 pacientes com ZIKV (27,3%) tiveram uma resposta de células T detectável aos peptídeos do ZIKV (C, NS2A, NS4A e NS5). A magnitude média das respostas anti-ZIKV foi de 89 SFC / 106 PBMC [IQR: 79-156]. NS5 foi a proteína imunodominante que foi reconhecida na maioria dos respondendores (5/9, 55,6%). Para análise de linfócitos T CD4 + a proporção de células que expressaram IFN-gama foi significativamente maior em todas as subpopulações de TCM, memória efetora (TEM) (CD45RA-CD27 + CCR7-) e memória de transição (TTM) (CD45RACD27 + CCR7-) de pacientes na fase P1 em comparação a fase P2 e controles saudáveis (p <0,005). Para o perfil de linfócitos T CD8 +, expansão das subpopulações TN, TCM, TEM, TEMRA e menor proporção da subpopulação TTM foram observados nos pacientes na fase P1 em comparação a controles saudáveis. Os pacientes na fase P2 exibiram uma proporção menor das subpopulações TEM e TEMRA em comparação com pacientes na fase P1. Conclusão. Os pacientes com ZIKV apresentarm manifestações clínicas leves e inespecíficas, com uma resposta imune celular de baixa intensidade e dirigida predominantemente para antígenos nãoestruturais.

Antiretroviral changes during the first year of therapy / Mudanças de terapia antirretroviral durante o primeiro ano de tratamento

Summary Introduction: The Brazilian HIV/AIDS management and treatment guideline (PCDT), published in 2013, recommends and standardizes the use of highly active antiretroviral therapy (HAART) in all adult patients, in spite of LTCD4 count. This study aimed to analyze the first year of HAART use in patients from a reference center on HIV/AIDS management in Fortaleza, Ceará. Method: This descriptive study reviewed all prescription forms of antiretroviral regimens initiation and changes from January to July 2014. All antiretroviral regimen changes that occurred during the first year of therapy were evaluated. Data were analyzed with SPSS version 20. Mean, standard deviation and frequency, Student's t and Mann-Whitney tests calculations were used, with significance at p<0.05. Results: From 527 patients initiating HAART, 16.5% (n=87) had a regimen change in the first year. These patients were mostly male (59.8%; n=52), aged 20 to 39 years, with only one HAART change (72.4%; n=63). Efavirenz was the most often changed drug, followed by tenofovir, zidovudine and lopinavir/ritonavir. Mean time of HAART changes was 120 days, with adverse reactions as the most prevalent cause. HAART was effective in decreasing viral load since second month of treatment (p=0.003) and increasing LTCD4 lymphocytes since fifth month (p<0.001). Conclusion: The main cause of initial HAART changes was adverse reaction and most patients had only one change in the HAART regimen. HAART prescription was in accordance to the PCDT from 2013.

Resumo Introdução: O Protocolo Clínico e Diretrizes Terapêuticas para manejo da infecção pelo HIV em adultos (PCDT) de 2013 recomenda e normatiza início de terapia antirretroviral (TARV) em pacientes com qualquer contagem de LTCD4. O objetivo do estudo foi analisar o primeiro ano de TARV de pacientes em acompanhamento em um centro de referência em HIV/AIDS de Fortaleza, Ceará. Método: O estudo descritivo revisou formulários de solicitação de início e modificação de TARV em pacientes que iniciaram tratamento entre janeiro e julho de 2014. Foram avaliadas todas as mudanças que ocorreram durante o primeiro ano de terapia. Os dados foram analisados no programa Statistical Package for the Social Sciences (SPSS) versão 20. Foram calculados médias, desvios padrão, frequências, testes t Student e Mann-Whitney, com significância de p<0,05. Resultados: Dos 527 pacientes que iniciaram TARV, 16,5% (n=87) realizaram troca no primeiro ano. A maioria era do sexo masculino (59,8%; n=52), de 20 a 39 anos, com apenas uma mudança da TARV (72,4%; n=63). Efavirenz foi o fármaco mais substituído, seguido por tenofovir, zidovudina e lopinavir/ritonavir. O tempo médio de ocorrência das modificações da TARV foi de 120 dias, tendo reações adversas como causas principais. TARV foi efetiva na queda da carga viral desde o 2ºmês de tratamento (p=0,003) e na elevação de LTCD4 desde o 5º mês (p<0,001). Conclusão: Os principais fatores envolvidos em modificações de TARV inicial foram reações adversas, com apenas uma mudança de esquema na maioria dos pacientes. O manejo da TARV estava de acordo com o PCDT de 2013.